Drug Design and Resistance Mechanisms in Mycobacterium Tuberculosis

Mycobacterium tuberculosis remains a global health threat, largely owing to its impermeable cell envelope, metabolic resilience and ability to acquire drug resistance. Contemporary drug design has combined rational, target-based approaches with phenotypic screening to identify inhibitors of key pathways such as mycolic acid synthesis, protein synthesis and nucleotide metabolism. Many frontline and second-line agents are administered as prodrugs that require activation by mycobacterial enzymes (for example KatG for isoniazid and EthA for ethionamide). Resistance mechanisms include mutations in drug‐activating enzymes or their promoters, modifications of drug targets, enzymatic drug inactivation, upregulation of efflux pumps and global transcriptional remodelling. Recent advances in structural biology have elucidated binding pockets of essential enzymes, enabling the design of booster molecules that block transcriptional repressors (such as EthR) and enhance prodrug efficacy. Omics approaches have uncovered novel resistance-associated genes and lineage-specific expression patterns, while genome-wide association studies have revealed alternative prodrug activators and metabolic factors influencing susceptibility. Nanoparticle-based co-delivery systems offer targeted pulmonary administration of drug–booster combinations, reducing systemic toxicity and overcoming solubility barriers. Together, these interdisciplinary strategies are driving the development of next-generation antitubercular therapies with improved potency against both drug-sensitive and resistant strains.

Research from Nature Portfolio

Recent studies have employed integrated omics analyses to map gene expression perturbations associated with ethionamide resistance. Investigation of a monooxygenase/repressor gene cluster identified Rv3094c as a key enzyme in prodrug sulfoxidation, revealing structural determinants of substrate binding and activation. These insights expand the repertoire of enzymes involved in drug activation beyond classic monooxygenases. In parallel, innovative formulations for co-encapsulation of ethionamide and its booster in biodegradable nanoparticles have been developed for direct pulmonary delivery. Preclinical evaluation demonstrated that nanoparticle-mediated co-delivery maintains drug activity, enhances lung retention and achieves a multi-log reduction in pulmonary bacterial load, paving the way for more effective and less toxic regimens.

Drug Design and Resistance Mechanisms in Mycobacterium Tuberculosis publication trend

The graph below shows the total number of articles in drug design and resistance mechanisms in mycobacterium tuberculosis across all publications each year (not limited to Nature Index journals).

Technical terms

Prodrug: A compound administered in inactive form that is bioactivated by microbial or host enzymes to exert its therapeutic effect.

Monooxygenase: An enzyme that introduces one atom of oxygen into a substrate, often critical for prodrug activation.

Minimum inhibitory concentration (MIC): The lowest drug concentration that prevents visible growth of a microorganism in vitro.

Transcriptional repressor (EthR): A protein that binds DNA to inhibit expression of genes, here controlling the ethionamide activator EthA.

Nanoparticle co-delivery: Encapsulation of two or more agents within a single nanoscale carrier to ensure simultaneous delivery to target tissues.

References

1. Omics analysis of Mycobacterium tuberculosis isolates uncovers Rv3094c, an ethionamide metabolism-associated gene. Communications Biology (2023).
2. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. Scientific Reports (2017).
3. Identification of Mycobacterium tuberculosis transcriptional repressor EthR inhibitors: Shape-based search and machine learning studies. Heliyon (2024).
4. Perchlozone Resistance in Clinical Isolates of Mycobacterium tuberculosis. Antibiotics (2023).
5. Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis. mBio (2019).